MedTrace Logo

MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry

NCT01347944 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 149

Last updated 2019-11-18

No results posted yet for this study

Summary

The purpose of this study is to collect clinical and laboratory data for patients affected by intermediate 1 and low risk Myelodysplastic Syndrome (MDS) associated by deletion 5q who were prescribed Revlimid from 31October 2008 to present. Revlimid is available in Italy for these patients since October 2008 based on a local disposition of the Italian Drug Agency (AIFA) issued according to a National law named 648/96.

Conditions

Interventions

DRUG

lenalidomide

Patients who were prescribed Revlimid from 31October 2008 to present.

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Sante Cundari, PhD, MSc · Celgene s.r.l.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01347944 on ClinicalTrials.gov